Regenicin Advances Autologous Cultured Skin Substitute Tiscela Toward FDA Clinical Trials for Severe Burns
核心洞察
Regenicin (搜索) is preparing an FDA-regulated clinical program for Tiscela (搜索), an autologous cultured skin substitute grown from a patient's own skin cells to treat catastrophic burns.
The process expands a 35-millimeter skin patch into a graft up to 100 times larger in about 28 days, reducing rejection risk and pain compared with traditional skin grafting.
The company's IND application targets patients with burns covering at least 20 percent of their body, with most expected cases involving one-third to 50 percent of body surface.
Regenicin (搜索), a biotechnology company based in Las Vegas with a laboratory at Roseman (University) Bioventures, is preparing a new FDA-regulated clinical program for Tiscela (搜索) (formerly known as NovaDerm), an autologous cultured skin substitute designed to treat catastrophic burns. The approach addresses what the company describes as a significant unmet need in severe burn care, where current treatment has long been limited to painful skin grafting that transplants healthy skin from one part of a patient's body to cover a wound.
The technology works by taking a small, postage-stamp-sized piece of a patient's own skin and growing it in the laboratory into a piece up to 100 times larger over approximately 28 days before applying it to the wound. "I didn't realize that there are companies that take skin cells from patients and they grow them and then they put them on those same patients because it reduces the chance of rejection," said Josh Axtell, a graduate student and lab assistant at Roseman who is writing his thesis on the company.
Addressing an Unmet Need in Severe Burn Care
Severe burns (搜索) cause one of the most excruciating forms of pain a person can endure, and the subsequent treatment has often proved more painful than the initial trauma. Dr. K.E. Castro, director of clinical trials for Regenicin (搜索), explained the limitations of current care. "If you have a significant enough part of your body that's been burnt, there's really very little that they can do to help you," Castro said. "The first thing doctors do is they remove all the damaged skin, which leaves your frayed nerves open. They patch it temporarily, but most unnatural patches, or things that aren't part of your body, are going to be rejected because of your immune system."
The current standard of care involves taking patches of skin from other parts of the patient's body, stretching them out, and applying them to the damaged area. However, as Castro noted, "the patient has already lost a lot of skin and now you're taking their healthy skin and you're moving it over. So it's painful on both sides, and it's very difficult to get enough skin to patch up 50 percent of your body."
Clinical Program and Patient Population
Regenicin (搜索)'s FDA Investigational New Drug (IND) application will target patients with burns over at least 20 percent of their body. "But we're expecting that most of our burn victims will be one-third of their bodies or 50 percent," Castro said. "When it gets to be 20 percent or more is when you really start to need this. Your nerves are frayed and it's permanent."
The manufacturing process begins by taking a 35-millimeter patch of skin from the patient, usually from the inner thigh. In the laboratory, the company grows millions of skin cells into billions. "We then take those cells, put them on a collagen scaffold that we developed, and they grow together, much like your natural skin would do when it was healing a part of your body," Castro said. "Then those patches become our cultured skin substitute. We're literally creating the transplant."
Castro described the immediate goal as providing a replacement for current treatment. "Ultimately we may be able to do more, but the goal right now is to be able to provide a replacement for the current treatment, allowing the patient to heal and basically feel far less pain in the process."
Funding and Development Timeline
Regenicin (搜索) was founded in 2010 and originally intended to finalize an IND application in 2016. Castro noted that a 15- to 20-year development timeline for a product intended for human use is typical. "The company's gone through a lot of shifts and changes and funding issues. Until 2022, we didn't have the funding to completely get through the clinical trial. But our strongest point right now is we're fully funded. We have enough to finish our initial clinical trial."
The company received almost $50 million in presale funding in 2022 and 2023, part of which covered the cost of the laboratory at Roseman, where Regenicin (搜索) has been headquartered since 2024. "Regenicin's approach brings donor-specific skin cell regeneration closer to reality, addressing a significant unmet need for patients with burns and other complex wounds," said Roseman Bioventures managing director Titus Plattel.
Orphan-Drug Designation and Path to Approval
The path toward FDA approval may be aided by the fact that the FDA previously granted the product an Orphan-Drug Designation, a special status given to medicines intended to prevent, diagnose, or treat rare diseases or conditions. "It's a designation for solutions to medical issues that have no good solution. In this case, they recognize that the current solution is not a good one," Castro said. "As a result, we've been told before by the FDA that we can do a very small clinical trial and get approval upon success."
In April, Regenicin (搜索) partnered with Made Scientific (搜索), a cell therapy contract development and manufacturing organization in Princeton, New Jersey, to advance Tiscela (搜索) toward a U.S. FDA orphan product approval. The company's next steps are to file the IND application and then conduct its first in-human clinical trials. "We're really close," Castro said. "Hopefully we get clearance to start a clinical trial next year and have our contracts with our burn centers during that time. If our orphan-drug application is successful, we may get approval by the end of next year. So 2027 would be the best of timelines. That is our goal right now."